Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rexlemestrocel-L - Mesoblast/Teva Pharmaceutical Industries

Drug Profile

Rexlemestrocel-L - Mesoblast/Teva Pharmaceutical Industries

Alternative Names: Allogeneic mesenchymal precursor cells - Mesoblast; Allogeneic STRO-3 immunoselected bone marrow-derived mesenchymal precursor cells (MPCs) - Mesoblast; CEP-41750; Mesenchymal stem cell therapy - Mesoblast; MPC 06; MPC-06-ID; MPC-150; MPC-150-IM; MPC-25; MPC-25-IC; MPC-25-Osteo; MPC-300; MPC-300-IV; MPC-75-IA; MPC-CBE; MPC-MICRO-IO; MSB-CAR001; NeoFuse; Replicart; Revascor

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanson Institute; Institute of Medical and Veterinary Science
  • Developer Angioblast Systems; Mesoblast; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antihypercalcaemics; Antineoplastics; Antirheumatics; Heart failure therapies; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heart failure; Haematological malignancies
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Heart failure; Hodgkin's disease; Intervertebral disc degeneration; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Myocardial infarction; Osteoarthritis; Rheumatoid arthritis; Spondylosis; Type 2 diabetes mellitus
  • Phase I/II Diabetic nephropathies
  • No development reported Age-related macular degeneration; Fracture; Lung disorders; Peripheral arterial disorders; Skin ulcer

Most Recent Events

  • 26 Nov 2019 Meoblast and the International Center for Health Outcomes Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai in New York agrees on the protocol in line with the US FDA guidance for a phase III trial in Heart failure
  • 26 Nov 2019 Mesoblast and Center for Health Outcomes Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai in New York plans a confirmatory phase III trial for Heart failure in the US
  • 10 Sep 2019 Mesoblast and Grunenthal enter into an alliance for the development, manufacture and commercialisation of Rexlemestrocel-L in Latin America and Europe for Chronic lower back pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top